Algorae Pharmaceuticals Ltd (AU:1AI) — Market Cap & Net Worth
Market Cap & Net Worth: Algorae Pharmaceuticals Ltd (1AI)
Algorae Pharmaceuticals Ltd (AU:1AI) has a market capitalization of $20.04 Million (AU$28.32 Million) as of May 6, 2026. Listed on the AU stock exchange, this Australia-based company holds position #25009 globally and #1085 in its home market, demonstrating a 16.67% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Algorae Pharmaceuticals Ltd's stock price AU$0.01 by its total outstanding shares 2023070155 (2.02 Billion). Analyse Algorae Pharmaceuticals Ltd operating cash flow efficiency to see how efficiently the company converts income to cash.
Algorae Pharmaceuticals Ltd Market Cap History: 2015 to 2026
Algorae Pharmaceuticals Ltd's market capitalization history from 2015 to 2026. Data shows change from $67.56 Million to $20.04 Million (-8.54% CAGR).
Algorae Pharmaceuticals Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Algorae Pharmaceuticals Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
142.08x
Algorae Pharmaceuticals Ltd's market cap is 142.08 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $120.24 Million | $120.09K | -$3.09 Million | 1001.26x | N/A |
| 2017 | $36.50 Million | $115.28K | -$4.09 Million | 316.64x | N/A |
| 2018 | $59.41 Million | $9.11K | -$374.49K | 6524.46x | N/A |
| 2019 | $21.61 Million | $9.77K | -$3.18 Million | 2212.60x | N/A |
| 2020 | $18.90 Million | $3.17K | -$968.47K | 5964.38x | N/A |
| 2021 | $7.73 Million | $268.18K | -$1.46 Million | 28.82x | N/A |
| 2022 | $17.03 Million | $3.41K | -$1.96 Million | 4995.39x | N/A |
| 2023 | $14.31 Million | $42.02K | -$2.11 Million | 340.66x | N/A |
| 2024 | $8.59 Million | $125.20K | -$2.10 Million | 68.60x | N/A |
| 2025 | $20.04 Million | $141.05K | -$802.96K | 142.08x | N/A |
Competitor Companies of 1AI by Market Capitalization
Companies near Algorae Pharmaceuticals Ltd in the global market cap rankings as of May 6, 2026.
Key companies related to Algorae Pharmaceuticals Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.67 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #364 globally with a market cap of $72.97 Billion USD.
- UCB SA (BR:UCB): Ranked #515 globally with a market cap of $51.41 Billion USD ( €43.97 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #570 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.67 Billion | $424.36 |
| #364 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.97 Billion | $702.27 |
| #515 | UCB SA | BR:UCB | $51.41 Billion | €231.00 |
| #570 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Algorae Pharmaceuticals Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Algorae Pharmaceuticals Ltd's market cap moved from $67.56 Million to $ 20.04 Million, with a yearly change of -8.54%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$20.04 Million | 0.00% |
| 2025 | AU$20.04 Million | +133.33% |
| 2024 | AU$8.59 Million | -40.00% |
| 2023 | AU$14.31 Million | -15.97% |
| 2022 | AU$17.03 Million | +120.37% |
| 2021 | AU$7.73 Million | -59.09% |
| 2020 | AU$18.90 Million | -12.58% |
| 2019 | AU$21.61 Million | -63.61% |
| 2018 | AU$59.41 Million | +62.75% |
| 2017 | AU$36.50 Million | -69.64% |
| 2016 | AU$120.24 Million | +77.97% |
| 2015 | AU$67.56 Million | -- |
End of Day Market Cap According to Different Sources
On May 6th, 2026 the market cap of Algorae Pharmaceuticals Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $20.04 Million USD |
| MoneyControl | $20.04 Million USD |
| MarketWatch | $20.04 Million USD |
| marketcap.company | $20.04 Million USD |
| Reuters | $20.04 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Algorae Pharmaceuticals Ltd
Algorae Pharmaceuticals Limited, a pharmaceutical development company, engages in the research and development of living cells technologies primarily in New Zealand. The company's product pipeline includes AI-116, a novel combination drug candidate made up of donepezil and cannabidiol for the treatment of dementia, including Alzheimer's disease; AI-168, a novel combination drug candidate made up … Read more